After twelve years of research, Prof. Abd Al-Roof Higazi and colleagues from Hadassah’s Department of Clinical Biochemistry, together with researchers at the University of Pennsylvania, have developed a substance that has the potential to revolutionize treatment of strokes. The substance, called a peptide, proved to stop the disastrous hemorrhaging in animal models that is often a side effect of medicine used to dissolve stroke-causing blood clots. Plans are underway to begin clinical trials in humans. Prof. Higazi is the Chief Scientific Officer of Thrombotec Ltd., a start-up company of Hadasit, Hadassah’s technology transfer company.

Prof. Higazi grew up in the Galilee village of Tamra, and lives with his family in Neve Shalom, a mixed Jewish-Arab village dedicated to coexistence. His peptide, he hopes, will turn the tide on stroke treatment.